A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-Endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer
Shun Lu, Chengping Hu(Central South University), Li Lü(Tongji Hospital), Shuliang Guo(Apple (Israel)), Baolan Li(Beijing Chest Hospital), Cheng Huang(Anhui Business College), Yi Luo(Kunming Institute of Botany), Gang Wu(Union Hospital), Ping Chen(Central South University), Li Zhang(Jinan Stomatological Hospital), Zhiwei Chen(Shanghai Jiao Tong University), Chunhong Hu(Central South University), Yiping Zhang(Zhejiang Cancer Hospital), Wei Li(Leshan Normal University), Yongfeng Yu(Shanghai Chest Hospital), Meilin Liao(Shanghai Chest Hospital), Li‐Yan Xu(Shantou University), Xiangqun Song(Tumor Hospital of Guangxi Medical University), Caicun Zhou(Tongji University)
Cited by 44
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k